Actively Recruiting
Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
Led by Qinghai Red Cross Hospital · Updated on 2026-04-30
326
Participants Needed
4
Research Sites
170 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.
CONDITIONS
Official Title
Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed solid tumors, including breast, lung, gastric, cervical, endometrial, ovarian, pancreatic cancers, or melanoma
- Age 18 years or older
- Scheduled to receive adjuvant or neoadjuvant taxane-based chemotherapy (paclitaxel, nab-paclitaxel, or docetaxel) for early disease, or advanced disease with no prior chemotherapy
- Life expectancy of at least 3 months
- ECOG performance status of 0 to 2
- Adequate function of major organs including heart, liver, kidneys, and bone marrow
- Willing and able to provide written informed consent and follow study procedures
You will not qualify if you...
- Severe major organ dysfunction preventing standard-dose chemotherapy
- Existing peripheral neuropathy or history of peripheral neuropathy
- Skin conditions that could interfere with CIPN symptom assessment, such as severe palmoplantar keratoderma or active skin infection
- Recent use of medications that relieve CIPN symptoms
- Difficulty swallowing, intestinal blockage, or conditions affecting drug absorption
- Known allergy or hypersensitivity to mecobalamin
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Affiliated Hospital of Qinghai University
Xining, Qinghai, China
Not Yet Recruiting
2
Qinghai Red Cross Hospital
Xining, Qinghai, China
Actively Recruiting
3
Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital)
Jinan, Shandong, China
Not Yet Recruiting
4
Beijing Chaoyang Sanhuan Cancer Hospital
Beijing, China
Actively Recruiting
Research Team
J
Jiuda Zhao, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here